Most T-ALL cell lines harbouring activating mutations in NOTCH-1 fail to respond to small-molecule γ-secretase inhibitors (GSIs) therapy, owing to mutational loss of the phosphatase and tensin homolog (PTEN) tumour suppressor26. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.